Skip to main content
. 2022 Jul 13;1(5):100400. doi: 10.1016/j.jscai.2022.100400

Table 1.

Patient characteristics.

N = ​23
Age, y 66.8 ​± ​9.5
Male 16 (70)
Female 7 (30)
Body mass index, kg/m2 27.9 ​± ​4.3
Follow-up, mos (range) 12 (8-14)
CAD risk factors
 Prior tobacco use 12 (52)
 Current tobacco use 5 (22)
 Diabetes mellitus 5 (22)
 Hypertension 22 (96)
 Hyperlipidemia 20 (87)
 Previous myocardial infarction 16 (70)
 Family history of CAD 11 (48)
Medications at index procedure
 Aspirin 23 (100)
 Calcium channel blocker 10 (43)
 Statin 23 (100)
 ACE-I/ARB 22 (96)
 Beta-blocker 17 (74)
Baseline laboratory data
 LDL, mg/dL 83 ​± ​32
 HDL, mg/dL 49 ​± ​16
 Total cholesterol, mg/dL 155 ​± ​36
 Triglycerides, mg/dL 128 ​± ​53
 Lipoprotein(a), mg/dL 34 ​± ​32
 hs-CRP, mg/L 1.3 ​± ​1.5
 MMP-9, ng/mL 3.7 ​± ​3.7
12-Month laboratory data
 LDL, mg/dL 56 ​± ​15
 HDL, mg/dL 46 ​± ​10
 Total cholesterol, mg/dL 125 ​± ​21
 Triglycerides, mg/dL 114 ​± ​43
 Lipoprotein(a), mg/dL 38 ​± ​42
 hs-CRP, mg/L 2.4 ​± ​4.3
 MMP-9, ng/mL 5.2 ​± ​4.3
Imaged vessel
 Left anterior descending artery 10 (43)
 Left circumflex artery 6 (26)
 Right coronary artery 7 (30)

Data are presented as mean ​± ​SD for continuous variables and n (%) for categorical variables. Missing laboratory data were omitted from calculations.

ACE-I/ARB, angiotensin-converting enzyme inhibitor/angiotensin receptor blocker; CAD, coronary artery disease; HDL, high-density lipoprotein; hs-CRP, high sensitivity C-reactive protein; LDL, low-density lipoprotein; MMP-9, matrix metalloproteinase-9.